Blinatumomab Biosimilar - Research Grade

Blinatumomab Biosimilar - Research Grade

Product Citations:

Mancusi et al. Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation. Int. J. Mol. Sci. 2023, 24(22), 16105

Product Details:

ichorbio's blinatumomab biosimilar is for Research Use Only (RUO)

Target:

CD19/CD3

Isotype:

Bispecific

Other Names:

MT103

Host:

CHO cells

Species Reactivity:

Human

Specificity:

Detects human CD19/CD3.

Purification Method:

This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background:

Blinatumomab is a bispecific T-cell engager (BiTE). It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.

Concentration:

1.0 - 5.0 mg/ml

Formulation:

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity:

>95% by SDS-PAGE and HPLC

Endotoxin:

≤ 1.0 EU/mg as determined by the LAL method

Storage:

Blinatumomab biosimilar - Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Applications:

Functional Assays

Application Notes:

Each investigator should determine their own optimal working dilution for specific applications.

Use: ichorbio's blinatumomab biosimilar is for research use only (RUO).